On August 10, 2022 Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and Alpine Immune Sciences, Inc. (NASDAQ: ALPN) reported that Evotec’s Seattle-based subsidiary, Just – Evotec Biologics, Inc., expanded a multi-year partnership with Alpine for the development of a commercial process for ALPN-303, an engineered TACI domain with significantly improved potency against the B cell cytokines BAFF and APRIL, being developed for the treatment of systemic lupus erythematosus and other B cell-mediated inflammatory and autoimmune diseases (Press release, Alpine Immune Sciences, AUG 10, 2022, View Source [SID1234617986]). The contract is a continuation of their first-in-human program initiated in 2020 in which Just – Evotec Biologics delivered drug substance materials using their J.DESIGN continuous manufacturing platform for Alpine’s ongoing Phase I study and anticipated Phase II studies of ALPN-303.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This press release features multimedia. View the full release here: View Source

Under the expanded contract, Just – Evotec Biologics will leverage its data-driven technology platform to develop a commercial manufacturing process for ALPN-303. The program includes upstream and downstream process, analytical method, and formulation development with a view to support commercial manufacturing of ALPN‑303. Commercial process development activities will be performed at Just – Evotec Biologics’ state-of-the art J.POD biomanufacturing facility located in Redmond, Washington.

J.DESIGN, Just – Evotec Biologics’ data-driven, highly automated end-to-end biologics technology platform, employs a series of innovative technologies relying on the use of artificial intelligence, machine learning, intensified and continuous bioprocesses specifically designed for flexible and efficient biologics development, from discovery through to clinical and commercial manufacturing. The advanced Just – Evotec Biologics platform is specifically well suited for monoclonal antibodies and related protein modalities such as Fc fusion proteins. The J.POD facility was designed to support both clinical and commercial manufacturing processes while leveraging its expandable and highly flexible capacity.

Dr Linda Zuckerman, Executive Vice President, Global Head Biotherapeutics at Just – Evotec Biologics, commented: "We are excited to continue our highly collaborative partnership with the innovative team at Alpine to support the development of a commercial process for ALPN-303 in our state-of-the-art J.POD site in Redmond, WA."

Dr Craig Johnstone, Chief Operating Officer at Evotec, added: "We are proud to support Alpine in its endeavor to further develop ALPN-303. The combination of flexible manufacturing capacity with smart, robust and high-yielding process development makes Just – Evotec Biologics’ J.DESIGN the ideal platform to bring ALPN-303 to patients with currently significant unmet medical needs."

Dr Wayne Gombotz, Alpine’s Chief Technology Officer, commented: "ALPN-303 is a highly differentiated and promising therapeutic candidate with the potential to treat challenging target diseases such as lupus and other B-cell related inflammatory diseases. We are excited to be leveraging Just – Evotec Biologic’s J.DESIGN platform to bring this important therapeutic to late-stage clinical development."

About ALPN-303

ALPN-303 is a dual B cell cytokine antagonist being developed for multiple autoimmune and/or inflammatory diseases. Engineered by directed evolution, ALPN-303 potently inhibits the pleiotropic B cell cytokines B cell activating factor/B lymphocyte stimulator (BAFF, BLyS) and a proliferation inducing ligand (APRIL), which play key roles in B cell development, differentiation, and survival, and together contribute to the pathogenesis of multiple autoimmune diseases like systemic lupus erythematosus (SLE) and many other autoantibody-related inflammatory diseases. By simultaneously blocking these two cytokines, ALPN-303 has the potential to improve outcomes in patients suffering from severe autoimmune and/or inflammatory diseases.

On August 10, 2022 Australian biotechnology company Starpharma reported it has signed a new DEP Research Agreement with MSD, the trade name of Merck Sharp & Dohme LLC, Rahway, NJ, USA (Press release, Starpharma, AUG 10, 2022, View Source [SID1234617967]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This new DEP program will generate and evaluate additional DEP Antibody Drug Conjugates (ADCs).

This new agreement follows an earlier DEP Antibody Drug Conjugate (ADC) agreement that Starpharma signed with MSD in February 2021 as well as an expanded DEP Research Agreement with another large US biopharmaceutical company in June 2022.

"We are very pleased to add this new DEP ADC program with MSD and to continue building on our partnership with them in such an innovative and valuable area. This new DEP program underlines the potential clinical and commercial value our DEP technology can deliver," said Dr Jackie Fairley, CEO of Starpharma.

"This is the second DEP partnering agreement that Starpharma has signed in the last two months, signifying increased momentum and interest in the DEP platform."

Antibody-drug conjugates (ADCs) have become an increasingly valuable class of therapeutic agents in oncology and hematology. The design of ADCs incorporates the specific cell targeting property of antibodies with the cell killing properties of chemically conjugated drugs, to provide a targeted therapeutic with minimal off target toxicities.

Starpharma’s DEP ADCs have the potential to overcome the limitation of relatively low drug loading that is a feature of first-generation ADCs. The DEP technology allows precise attachment of drug loaded dendrimer(s) to targeting molecules with a high load of covalently link drug (4, 8,16, 32 drug molecules per dendrimer) providing a selective, homogeneous ADC with a significantly higher drug-antibody ratio (DAR) as compared to currently available ADCs.

Starpharma has previously demonstrated the advantages of DEP in ADCs in multiple preclinical studies, including for DEP HER-2 ADC, which showed significant tumour regression and 100% survival, outperforming Herceptin & Kadcyla in a human ovarian cancer model. DEP ADCs are the subject of both internal and partnered DEP programs.

Starpharma has multiple DEP partnerships with leading, international companies, including AstraZeneca, MSD, and Chase Sun, and the company’s DEP technology has already yielded four clinical-stage oncology products.

On August 10, 2022 Patrys reported to share promising new preclinical research results (Press release, Patrys, AUG 10, 2022, View Source [SID1234617951]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A new animal study has found that PAT-DX1, in combination with radiation therapy, improves survival in an animal model of brain cancer.

The study, which was conducted in the laboratory of Professor Terrance Johns at the Telethon Kids Cancer Centre, showed that combining a therapeutic dose of radiation with PAT-DX1 resulted in significantly prolonged survival in mice, compared to radiation treatment alone.

Additionally, the data also showed that even at a lower dose, PAT-DX1 as a single agent showed significant activity, confirming previous studies in brain cancer models

These results provide strong support for the potential use of PAT-DX1 to improve outcomes for patients with high-grade glioma – an aggressive and clinically challenging form of brain cancer.

Professor Terrance Johns said:

"These impressive results offer the potential for future clinical strategies that allow the reduction of radiation doses and its associated side effects, particularly in children. We are excited to be working with Patrys as we work to optimize strategies for combining standard of care with PAT-DX1 therapies."

On August 9, 2022 Blue Water Vaccines Inc. ("BWV" or "Blue Water Vaccines" or "the Company"), a biopharmaceutical company developing transformational vaccines to address significant global health challenges, reported that it has entered into definitive agreements with several healthcare-focused institutional investors for the purchase of 3,683,280 shares of common stock (or common stock equivalents in lieu thereof) in a private placement priced at-the-market under Nasdaq rules (Press release, Onconetix, AUG 9, 2022, View Source [SID1234641112]). The Company will also issue to the investors unregistered preferred investment options (the "investment options") to purchase up to an aggregate of 4,972,428 shares of common stock. The purchase price for one share of common stock (or common stock equivalent) and one investment option to purchase one share of common stock is $2.715. The investment options will have an exercise price of $2.546 per share, will be exercisable immediately upon issuance, and will have a term equal to five years following the issuance date.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

The gross proceeds from the private placement are expected to be approximately $10 million, before deducting placement agent fees and other offering expenses. The Company intends to use the net proceeds from the private placement for the research and development of its pipeline as well as for working capital and other general corporate purposes. The Company’s current cash position including the expected gross proceeds from this private placement is approximately $30.3 million. The private placement is expected to close on or about August 11, 2022, subject to the satisfaction of customary closing conditions.

The offer and sale of the foregoing securities are being made in a transaction not involving a public offering and the securities have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), or applicable state securities laws. Accordingly, the securities may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. Pursuant to a registration rights agreement with investors, BWV has agreed to file a resale registration statement covering the securities described above.

In addition, the investors in the private placement agreed to cancel preferred investment options to purchase up to an aggregate of 1,180,812 shares of the Company’s common stock issued in April 2022.

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

On August 9, 2022 Helix BioPharma Corp. (TSX: "HBP") ("Helix" or the "Company"), a clinical-stage biopharmaceutical company that is developing unique therapies in the field of immuno-oncology based on its proprietary technology platform DOS47, reported that it has entered into a two-year scientific collaboration agreement ("Agreement") with University Hospital Tuebingen (Germany) to assess the therapeutic response of L-DOS47 in several cancer models expressing CEACAM6, with advanced preclinical metabolic imaging (Press release, Helix BioPharma, AUG 9, 2022, View Source [SID1234619306]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

We aim to explore the potential synergistic effects of L-DOS47 in combination with checkpoint inhibitors on relevant cancer models. To accomplish this overarching aim, Helix established a two-year collaborative partnership with a unique team from the University Hospital Tuebingen to gain further insights into the effects of L-DOS47 on the tumor microenvironment and pH modulation in vivo. In addition, the collaboration also explores the potential for designing novel LDOS47-based radiotracers with application in translational immune-oncology and molecular imaging.

Mr. Artur Gabor, CEO of Helix, commented, "We are excited to collaborate with the University Hospital of Tuebingen and especially the Medical Faculty, which have relevant experience and knowledge in molecular imaging, particularly the method of AcidoCEST, which makes pH changes in the tumor microenvironment visible through a color change. We expect this collaboration to result in new and additional insight into the therapeutic response of L-DOS47 in several not yet explored preclinical cancer models expressing CEACAM6."

Prof. André F. Martins (Ph.D., Department of Preclinical Imaging and Radiopharmacy) and Manfred Kneilling (MD, Department of Preclinical Imaging and Radiopharmacy & Department of Dermatology) of the University of Tuebingen said, "We are pleased to work with Helix on this exciting project. Our technological advances combined with Helix’ L-DOS47, which has already shown promising preclinical and clinical safety data, will allow us to gain further insights into its unique mechanism of action. L-DOS47 might be in combination with immune check point inhibitor-based immunotherapies and other targeted therapies applicable to promote tumors regression and thus to improve the treatment efficacy and hopefully long-term survival." Prof. Martins and Kneilling are members of the "Image-Guided and Functionally Instructed Tumor Therapies" (iFIT) Cluster of Excellence at the University of Tuebingen. iFIT is the only oncology-based cluster in Germany, a research consortium aiming to develop innovative and sustainable cancer therapies.